Tirzepatide 2.5mg/0.6ml: what the starter dose is really for

What SURMOUNT-1 tells us about how tirzepatide builds its effect

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity over 72 weeks. Participants started at 2.5mg weekly and moved through escalating doses (5mg, 7.5mg, 10mg, 12.5mg and 15mg) in roughly four-week steps. By the end of the trial, those on the 15mg maintenance dose had achieved an average body-weight reduction of around 20–21%.

That headline figure is easy to focus on. What it obscures is that every participant spent their first four weeks at exactly the dose you may be taking now. The trial was not designed to measure how much weight people lost at 2.5mg specifically; it was designed as a dose-escalation programme. The starting dose existed, by design, to lower the likelihood of nausea and gastrointestinal discomfort during the adjustment period — not to drive weight reduction.

This framing matters because people who expect the 2.5mg phase to produce visible results sometimes question whether their treatment is working. It is working: it is doing precisely what the trial design and the licensed prescribing schedule intend. NICE's appraisal of tirzepatide, TA1026, reflects this same graduated approach in its recommendations for ongoing clinical assessment at each stage of treatment.

Why 2.5mg/0.6ml is a tolerability dose, not a therapeutic ceiling

Tirzepatide slows how quickly the stomach empties and reduces appetite through its dual action on GIP and GLP-1 receptors. Both of those effects become more pronounced at higher doses. At 2.5mg, the receptor activation is present but modest; your digestive system is adjusting to a new signal it has never received before.

Gastrointestinal side effects (nausea, loose stools, indigestion, a feeling of fullness that arrives faster than expected) are most commonly reported in the early weeks of treatment or after a dose increase. Starting low gives the body time to adapt, which is why the licensed schedule specifies at minimum four weeks at 2.5mg before any increase is considered. Rushing that step does not speed up the outcome; it tends to increase side effects and can make treatment harder to sustain.

For a fuller picture of what happens when the dose moves on, most people begin to notice more meaningful appetite changes when they reach tirzepatide 5mg, which you can read about in detail on our tirzepatide 5mg page. The 2.5mg phase is the foundation, not the measure of how well tirzepatide will work for you personally.

What a prescriber looks for before moving beyond 2.5mg

No dose increase should happen automatically. A prescriber reviews how the 2.5mg phase has gone, specifically whether side effects have been manageable, whether the injection technique is correct and whether there are any clinical reasons to pause before escalating. At nume, every repeat is reviewed by a GPhC-registered Independent Prescriber before it is dispensed; the review is the same whether it is the first pen or the fifth.

The questions worth bringing to that review: how your appetite and energy have felt during the four weeks, any side effects and when they were worst, and whether anything in your health or medicines has changed. Those details shape how your prescriber thinks about moving forward. Our clinical team hears these questions regularly, and the answers genuinely influence individual prescribing decisions.

If you are weighing up whether to start treatment at all, the full dose schedule sets out the complete titration pathway so you can see the whole course before committing. Cost is a reasonable consideration too; the pricing page sets out what to expect transparently.

Practical points for the 2.5mg injection itself

Each 2.5mg KwikPen contains four weekly doses of 0.6ml each. The pen is pre-filled and pre-set, you do not draw up or measure the dose yourself. Injection sites are the abdomen, thigh or upper arm; rotating the site each week helps avoid skin reactions at any one spot.

Storage matters more than people sometimes expect. Pens should be kept refrigerated at 2–8°C until you are ready to use them. The exact window for keeping a pen at room temperature before it must be discarded is specified in the Patient Information Leaflet that comes with your prescription; always follow that leaflet rather than any figure cited online.

If you miss a dose, the Patient Information Leaflet and your prescriber are the right sources of guidance, instructions vary by how much time has passed. The FAQs page covers common practical questions, and the contact page connects you with the aftercare team seven days a week if something comes up between reviews.

When you are ready to think about starting treatment, the free consultation is the place to check your eligibility with one of our prescribers.